topotecan has been researched along with Animal Mammary Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borst, P; de Water, N; Gunnarsdottir, S; Jaspers, JE; Jonkers, J; Kersbergen, A; Nygren, AO; Pajic, M; Rottenberg, S; van der Burg, E; van Tellingen, O; Zander, SA | 1 |
| Borst, P; Greenberger, L; Jonkers, J; Rottenberg, S; Sol, W; van Tellingen, O; Zander, SA; Zhang, Y | 1 |
2 other study(ies) available for topotecan and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Genes, p53; Mammary Neoplasms, Animal; Maximum Tolerated Dose; Mice; Mice, Knockout; Phthalazines; Piperazines; Topoisomerase I Inhibitors; Topotecan | 2010 |
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; BRCA1 Protein; Camptothecin; Diketopiperazines; DNA Topoisomerases, Type I; Female; Gene Expression; Heterocyclic Compounds, 4 or More Rings; Irinotecan; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Mutation; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2012 |